Growth hormone
CJC-1295
Long-acting GHRH analog (with or without DAC)
CJC-1295 is a modified version of growth hormone-releasing hormone designed to last longer in the body. It was never approved by the FDA, and federal advisers have voted against allowing pharmacies to compound it.
Key facts
- Commonly discussed for: raising growth hormone and IGF-1.
- Evidence (C): The main human data are two small randomized, placebo-controlled trials in healthy adults (published 2006) that measured hormone levels, not health outcomes. No efficacy trials for a medical condition have been published.
- FDA status: Not recommended. On December 4, 2024 the PCAC voted 0-13 against adding CJC-1295 (free base) to the 503A Bulks List, agreeing with FDA, and the related salt forms were also rejected.
- Legitimate access: No clear legal route yet.
- Last reviewed: October 1, 2026.
Read the deep dives
Sources
- Teichman et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 2006
- FDA: December 4, 2024 Pharmacy Compounding Advisory Committee summary minutes
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list)